Get the Stockscreener App
15.33
0.59%
0.11
Tonix Pharmaceuticals Holding Corp stock is traded at $15.33, with a volume of 80,830.
It is up +0.59% in the last 24 hours and down -22.05% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$15.22
Open:
$15.2
24h Volume:
80,830
Relative Volume:
0.11
Market Cap:
$195.91M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.3615
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-3.22%
1M Performance:
-22.05%
6M Performance:
-56.85%
1Y Performance:
-51.01%
1-Day Range:
$15.00
$15.42
1-Week Range:
$15.00
$16.95
52-Week Range:
$7.31
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.32 | 194.63M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Fibromyalgia and migraine drug maker to share brain research in SF - Stock Titan
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
TNXPTonix Pharmaceut Latest Stock News & Market Updates - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026 - Sahm
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockSwing Trading Ideas & Explosive Capital Gains - bollywoodhelpline.com
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
Recap Report: How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockQuarterly Risk Review & Low Risk High Win Rate Picks - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Technical Overview & Free Community Consensus Stock Picks - DonanımHaber
Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail tradersAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Tonix licenses S1R antagonist from Rutgers University - BioWorld MedTech
Tonix Pharma secures rights to TNX-4900 for pain management - MSN
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Secures Global Rights for Promising Pain Treatment - GuruFocus
Tonix Pharmaceuticals Licenses Non-Opioid Pain Medicine Candidate From Rutgers University - marketscreener.com
Tonix Pharma Secures Rights to TNX-4900 for Pain Management - TipRanks
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug - Investing.com
Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain - TradingView — Track All Markets
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - The Manila Times
Tonix Pharmaceuticals Licenses TNX-4900, a Non-Opioid Analgesic with Promising Efficacy and Safety Profile for Neuropathic Pain - Quiver Quantitative
Tonix Pharmaceuticals announces licensing TNX-4900 - marketscreener.com
Tonix Pharmaceuticals Holding Corp. Announces That It Licensed Exclusive Rights to Its Tnx-4900 Product Candidate for Chronic Neuropathic Pain from Rutgers University - marketscreener.com
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Announces Licensing TNX-4900, a - GlobeNewswire
(TNXP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):